These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 9553009)

  • 1. Economic benefit analysis of primary prevention with pravastatin. Modelling economic benefits after such long term treatment is inappropriate.
    Pharoah P
    BMJ; 1998 Apr; 316(7139):1241-2. PubMed ID: 9553009
    [No Abstract]   [Full Text] [Related]  

  • 2. Economic benefit analysis of primary prevention with pravastatin. Assumptions are methodologically flawed.
    Freemantle N; Mason J
    BMJ; 1998 Apr; 316(7139):1241-2. PubMed ID: 9583930
    [No Abstract]   [Full Text] [Related]  

  • 3. [Victory in primary prevention--or? Can we afford to translate results from the West-of-Scotland Study into general practice?].
    Klose G
    Fortschr Med; 1996 Jun; 114(17):231-2. PubMed ID: 8767302
    [No Abstract]   [Full Text] [Related]  

  • 4. Prevention of coronary heart disease with pravastatin.
    Samani NJ; de Bono DP
    N Engl J Med; 1996 May; 334(20):1333-4; author reply 1334-5. PubMed ID: 8609957
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan.
    Nagata-Kobayashi S; Shimbo T; Matsui K; Fukui T
    Int J Cardiol; 2005 Sep; 104(2):213-23. PubMed ID: 16168816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of coronary heart disease with pravastatin.
    Davis DR
    N Engl J Med; 1996 May; 334(20):1334; author reply 1335. PubMed ID: 8609958
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevention of coronary heart disease with pravastatin.
    Rogers S
    N Engl J Med; 1996 May; 334(20):1333; author reply 1334-5. PubMed ID: 8609956
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term follow-up of the West of Scotland Coronary Prevention Study.
    DeFilippis AP; Bansal S; Blumenthal RS
    N Engl J Med; 2008 Jan; 358(2):194; author reply 194-5. PubMed ID: 18193527
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term follow-up of the West of Scotland Coronary Prevention Study.
    Tsubokura M; Kami M
    N Engl J Med; 2008 Jan; 358(2):193-4; author reply 194-5. PubMed ID: 18193526
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term follow-up of the West of Scotland Coronary Prevention Study.
    McEvoy JW; Margey R; Blake GJ
    N Engl J Med; 2008 Jan; 358(2):193; author reply 194-5. PubMed ID: 18184967
    [No Abstract]   [Full Text] [Related]  

  • 11. Statin therapy for prevention of coronary artery disease with average cholesterol levels.
    Gambhir DS
    Indian Heart J; 1999; 51(1):19-20, 105. PubMed ID: 10327772
    [No Abstract]   [Full Text] [Related]  

  • 12. Prevention of mortality from coronary heart disease with pravastatin.
    Tonkin AM; Ryan EW
    Biomed Pharmacother; 1999 Oct; 53(9):405-8. PubMed ID: 10554675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of pravastatin on coronary events after myocardial infarction.
    Auerbach I; Behar S; Motro M
    N Engl J Med; 1997 Mar; 336(13):962. PubMed ID: 9072702
    [No Abstract]   [Full Text] [Related]  

  • 14. [Basic principles of cost-benefit analysis in long-term treatment of risk factors].
    Szucs TD; Gutzwiller F
    Schweiz Med Wochenschr; 1998 Dec; 128(49):1958-64. PubMed ID: 9887476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overlap analysis of the West of Scotland coronary prevention study (WOSCOPS).
    Lim PO; Yee KM
    Circulation; 1999 Aug; 100(6):686. PubMed ID: 10441109
    [No Abstract]   [Full Text] [Related]  

  • 16. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin.
    Caro J; Klittich W; McGuire A; Ford I; Norrie J; Pettitt D; McMurray J; Shepherd J
    BMJ; 1997 Dec; 315(7122):1577-82. PubMed ID: 9437275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pravastatin and coronary heart disease.
    Bloom JM
    N Engl J Med; 1999 Apr; 340(14):1116-7. PubMed ID: 10206831
    [No Abstract]   [Full Text] [Related]  

  • 18. A need to redefine the consensus on the use of statins in coronary heart disease prevention.
    Fruchart JC
    Eur Heart J; 2000 Oct; 21(19):1572-3. PubMed ID: 10988008
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model.
    Muls E; Van Ganse E; Closon MC
    Atherosclerosis; 1998 Apr; 137 Suppl():S111-6. PubMed ID: 9694550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
    Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
    Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.